Metastatic Prostate Small Cell Carcinoma: Clinical Trials

2 active not recruiting. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Active not recruiting 2

Follow Metastatic Prostate Small Cell Carcinoma: new trials by email Literature Review of Metastatic Prostate Small Cell Carcinoma trials Research Report on Metastatic Prostate Small Cell Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma	Phase 2	Active not recruiting	Rahul Aggarwal	61	2021-01-26	2026-07-23
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma	Phase 2	Active not recruiting	M.D. Anderson Cancer Center	120	2020-12-29	2026-09-09

Narrower conditions

Prostatic Neoplasms (2)

Broader conditions

Genital Diseases (2)  ·  Genital Diseases, Male (2)  ·  Genital Neoplasms, Male (2)  ·  Male Urogenital Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Prostatic Diseases (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)

Interventions

Carboplatin (1)  ·  XRP6258 (1)  ·  cabazitaxel (1)  ·  enzalutamide (1)  ·  niraparib (1)  ·  pembrolizumab (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  Rahul Aggarwal (1)

Countries

United States (2)

Top investigators

Ana Aparicio (1)  ·  Rahul R Aggarwal, MD (1)